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Abstract
A lack of effective treatment for patients with treatment-resistant depression (TRD) has led to the evaluation of ketamine, an N-me-
thyl-D-aspartate receptor antagonist. Despite the demonstrated short-term benefits of using intravenous (IV) ketamine, side effects and 
the difficulty in administering ketamine outside the health-care setting has raised interest in alternative dosage forms. Research articles 
evaluating oral or intranasal (IN) ketamine were retrieved from the PubMed database. Patients who received oral or IN ketamine experien-
ced a similar reduction in depressive symptoms within 24 hours of treatment and fewer side effects compared to patients who received IV 
ketamine. Novel administration forms of ketamine provide an opportunity for patients with TRD to achieve remission with fewer adverse 
side effects. Future studies should continue to evaluate these administration strategies in the hope of promoting ketamine’s use outside 
health-care settings and for longer time periods. 
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Introduction
Depression affects over 350 million people worldwide.1 Major 
depressive disorder (MDD) is defined as a patient demonstrating 
at least five of the following nine symptoms for more than two 
weeks: depressed mood, poor sleep, loss of interest in daily ac-
tivities or hobbies an individual used to enjoy, feelings of guilt or 
worthlessness, reduced energy or chronic fatigue, poor concen-
tration, lack of appetite or five percent change in weight (gain 
or loss), physical and/or psychomotor agitation/retardation, and 
recurrent suicidal thoughts.2
The current standard of care for depression is primarily phar-
macologic therapies that can alter neurological function of mo-
noaminergic receptors within the central nervous system (CNS). 
These include serotonin selective reuptake inhibitors (SSRIs), 
serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic 
antidepressants (TCAs), and anti-psychotics. Treatment-resistant 
depression (TRD) is defined as MDD that does not adequately 
respond to treatment after appropriate courses of time with at 
least two anti-depressants.3 Inadequate response can be clas-
sified as either a complete lack of response or as the patient’s 
failure to achieve complete remission.4 Unfortunately, SSRIs and 
other first-line pharmaceutical treatments for depression take 
days or weeks to show clinical improvement, and produce an 
adequate response in less than two-thirds of patients.5
Despite the lack of research into novel treatments for TRD, one 
new therapy that has been tested to try and achieve better out-
comes for patients who have not had success with more tradi-
tional pharmacotherapies is ketamine.6,7 Ketamine is categorized 
as an N-methyl-D-aspartate (NMDA) receptor antagonist, but it 
has been identified to affect the metabolism of acetylcholine, 
opioids, monoamines, and interact with multiple ion channels 
throughout the body.8 Ketamine can be administered in intra-
venous (IV), intranasal (IN), and oral forms, among others. It is 
metabolized into norketamine, the more abundant and active 
metabolite, and dehydronorketamine, the inactive metabolite. 
IV forms of ketamine produce plasma concentrations of norke-
tamine that remain below initial ketamine levels, whereas oral 
forms produce much higher norketamine levels compared to ini-
tial ketamine doses.8
Evidence from numerous studies implicates alteration in the 
functions of the prefrontal, subcortical, and limbic brain systems 
in MDD.9,10 These regions of the brain are responsible for regu-
lating executive functions like decision-making, emotional-pro-
cessing, and social behavior.10 Patients suffering from MDD have 
been shown to have increased sensitivity to negative stimuli, 
such as pain and suffering, which directly relates to increased 
activity in the limbic and subcortical regions. By contrast, pa-
tients in remission from MDD commonly show increased activi-
ty in the pre-frontal cortex (PFC), which directly relates to the 
upregulation of glutamate activity in the PFC.11 Ketamine is an 
attractive alternative treatment for TRD due to its ability to si-
multaneously reduce neural activity in the limbic and subcor-
tical regions while increasing activity in the PFC.11-14 A single IV 
infusion of ketamine has been shown to improve the mental 
well-being of TRD patients in as little as thirty minutes.15,16 This 
could make ketamine a viable treatment option in patients who 
are unsuccessfully treated with conventional anti-depressant 
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therapies.17
Despite the potential of ketamine for the treatment of MDD, 
there are several factors that have limited its use in the Uni-
ted States and Canada, among other countries. Firstly, ketamine 
treatments are expensive and given that the United States Food 
and Drug Administration has not yet approved ketamine for the 
treatment of depression, these costs are not covered by insu-
rance (Available from: http://www.rxlist.com/script/main/art.
asp?articlekey=184155, cited 2015 Apr 11). Secondly, ketamine 
treatments are currently limited to IV administration by health 
care professionals which can make it more difficult for patients 
to access treatment.18 Lastly, ketamine can cause side effects 
such as dissociative amnesia, hallucinations, changes in blood 
pressure, and decreased cognition.8 Although these impairments 
are temporary, ketamine has only been tested over short time 
periods, which raises concern regarding its potential long-term 
impacts on mental function.19-21
Although IV ketamine has demonstrated rapid antidepressant 
effects, its disadvantages has led to the investigation of IN or 
oral dosage forms of ketamine treatment.6,18 The major goals of 
these alternative dosage forms are to reduce the dose required 
to achieve a therapeutic effect and to enable patient self-admi-
nistration. Oral administration requires greater metabolism in 
the liver, which despite having a lower bioavailability, produces 
higher serum norketamine levels, which has been associated 
with the increased potency of analgesia as well as prolonged 
duration of action.8 IN ketamine, which has been successfully 
used for other clinical purposes including pediatric operations, 
migraine headaches and chronic pain, has been shown to be 
safe, effective, and equally as potent as IV ketamine.8 This suc-
cess could result in reduced doses for TRD patients, which may 
limit the risk of adverse effects. 
This paper aims to review the current evidence behind the use 
of oral and IN ketamine in treating patients with TRD. A com-
parison will be made between these novel dosage forms and 
the pre-existing body of evidence regarding the use of IV ke-
tamine for TRD. Success of these interventions will be based 
on treatment response, length of symptom remission period, 
and presence of side effects. It is hypothesized that oral and 
IN dosage forms of ketamine are as effective as IV forms in the 
management of TRD.
Search Strategy and Selection Criteria
The database PubMed (1964-17 December 2014) was searched 
using the terms: “ketamine" and "depression", and two sepa-
rate searches were conducted using these two terms along 
with "intranasal administration " and "oral administration". In 
PubMed, all of these terms were searched both as basic terms 
and "MeSH" terms. The authors examined titles and abstracts 
that assessed the use of oral or (IN) ketamine in: (1) human 
subjects; (2) patients with (TRD); (3) randomized controlled 
trials (RCTs), case-control, cohort, or case series; (4) published 
in English; and (5) full reports (not just abstracts). This infor-
mation was extracted and organized in tabular form. Articles 
that did not meet these criteria were excluded. Full text articles 
were obtained and classified according to the route of admi-
nistration that was used in the study (IN or oral). Articles that 
did not address the administration of oral or IN ketamine were 
also excluded. Figure 1 provides an outline of the methodology 
used to retrieve articles for this review. The quality of a study 
was evaluated using the criteria from the Centre for Eviden-
ce-Based Medicine, Oxford (Available from: http://www.essen-
tialevidenceplus.com/product/ebm_loe.cfm?show=oxford, cited 
2014 Dec 17).
Results of the Search
As outlined in Figure 1, seven articles were included in this review. 
Two articles evaluated IN administration of ketamine, one being 
RCT while the other is a case-series. The other five articles evalua-
ted the efficacy of oral administration, but have been subdivided 
based on the demographics of the patient population in the study. 
Three studies focused specifically on patients with TRD, and all 
three are case studies. The other two studies on oral adminis-
tration evaluated efficacy in patients with TRD and a history of 
anxiety disorder. One of these is a case-series, and the second is 
an open-label trial. These articles are outlined in Table 1 and will 
be described in further detail below.
Intranasal Ketamine
The first of two studies conducted to date on the use of IN 
ketamine in TRD was a case-series comparing bipolar symp-
toms in 12 pediatric patients with TRD one to two weeks before 
and after treatment with six 10 mg doses of IN ketamine over 
a 20 week period.22 The second was a randomized-controlled 
cross-over trial which used two 50 mg IN ketamine doses and 
IN saline as control over two days in 18 patients with MDD.18 
Patients in the first study reported a 48% reduction (p < 0.001) 
in symptom severity and improvements in attention, execu-
tive function, and mood after receiving treatment according 
to the mean values of the Child bipolar questionnaire, Overt 
aggression scale, and Yale-Brown obsessive-compulsive scale.22 
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Figure 1. Flow Diagram for Article Screening and Selection
Records identified 
through database search 
(n=1,292)
Duplicates removed 
(n=130)
Full-text articles 
assessed for eligibility 
(n=212)
Abstracts screened 
(n=1,162)
Studies included 
(n=7)
Records excluded based 
on eligibility criteria 
(n=950)
Excluded because the following 
eligibility criteria were not met: 
• Human subjects
• Patients with treatment-resistant 
depression
• Randomized controlled trials,  
case-control, cohort, or case series
• Published in English
• Full reports (not just abstracts)
(n=205)
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Therapeutic effects were typically reached within one hour of 
treatment, and all patients had a reduction in symptoms after 
24 hours. Ketamine treatment kept all patients in remission 
from symptoms, but as the effects of the drug wore off, symp-
toms recurred.
Patients in the treatment group of the second study reported a 
significant reduction in their MDD symptoms compared to pla-
cebo. The mean difference in scores using the Montgomery-As-
berg Depression Rating Scale was 7.6 ± 3.7 (95% CI 3.9 - 11.3, p 
< 0.001).18 Additionally, eight patients (44%) experienced these 
reductions within 24 hours of receiving treatment compared 
to only one patient (6%) in the control group (number nee-
ded to treat = 2.6). Patients in this study18 reported minimal 
side effects from treatment, most commonly being dissociation 
(42%), poor memory (37%), and fatigue (26%) while more than 
65% of patients in the first study22 reported experiencing a loss 
of balance, dissociative effects, and dizziness as a result of 
treatment according to the Clinician administered dissociative 
states scale. These symptoms, with rare exceptions, were gone 
within 24 hours.22
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Study Study Design
Level of 
Evidence*
Study Population Therapy or Exposure Outcomes and Results
Papolos et 
al (2013)
Case series 4 12 pediatric (6-19 
years) patients with 
bipolar disorder and 
“fear of harm” phe-
notype
Comparison of bipolar symptoms pre- 
(1-2 weeks prior) and post-treatment 
with six 10mg doses of intranasal 
ketamine over a 20 week period. 
Measured using the child bipolar 
questionnaire, overt aggression scale, 
Yale Brown obsessive compulsive 
scale, and clinical administered 
dissociative states scale.
Intranasal ketamine led to large reductions in 
mania, fear of harm, and aggression. Improve-
ments in mood, anxiety, behavioral symptoms, 
attention/executive functions, insomnia, para-
somnia, and sleep inertia were also observed 
post-treatment.
Lapidus et 
al (2014)
Randomized 
controlled 
trial
1b 18 patients with major 
depressive disorder 
completed 2 treatment 
days with intranasal 
ketamine (50mg) or sa-
line solution (control)
Change in depression severity 24 
hours after treatment using Mont-
gomery-Asberg Depression Rating 
Scale. Also measured changes in 
self-reported depression, anxiety, and 
adverse effects.
Significant improvement in depressive symp-
toms at 24 hours in patients given ketamine 
compared to placebo. Minimal psychomimetic, 
dissociative, or hemodynamic side effects were 
observed.
Iglewicz et 
al (2013)
Case series 4 31 inpatients receiving 
hospice care being 
treated with ketamine 
for depression
Retrospective review of patients the-
rapeutic improvement, global impro-
vement, time to therapeutic effect, 
and side effects of oral ketamine 
during 4 time intervals (days 0-1, 2-3, 
4-7, and 8-21) over 21 days using 
Clinical Global Impression Scale.
Significant therapeutic improvements were seen 
during the first 7 days (especially in the first 
day). Global improvement was improved for all 
21 days. A majority of patients experienced no 
side effects, and any recorded side effects did 
not significantly impair functioning.
Irwin et al 
(2013)
Open-label 
proof-of-con-
cept trial
2b 14 patients with de-
pression or depression 
+ anxiety
Rating of overall depression and 
anxiety symptoms at baseline, and 
at days 3, 7, 14, 21, and 28 during 
course of daily oral ketamine (0.5 
mg/kg) over 28 day trial.
Significant improvements in depressive and 
anxiety symptoms were seen throughout the 28 
day trial. Maximum improvements were seen at 
days 14 and 3 for each symptom, respectively. 
Side effects were rare.
Irwin & 
Iglewicz 
(2010)
Case series 4 2 patients with depres-
sion + anxiety
Rating of overall depression and 
anxiety symptoms using the Hospital 
Anxiety Depression Scale at 1h, 2h, 
and day 8 (2nd patient) or day 15 
(1st patient) after a 0.5 mg/kg dose 
of oral ketamine.
Significant improvements in depressive and 
anxiety symptoms were seen in both patients 
throughout the course of follow up. Side effects 
were minimal in both patients.
Lara et al 
(2013)
Case series 4 26 outpatients with 
unipolar or bipolar 
depression showing 
unsatisfactory response 
to at least 4 other 
pharmacological 
treatments
Patient ratings of therapeutic effects 
and tolerability of sublingual ketami-
ne 0.5 mg/kg every 2-3 days for no 
more than 6 months.
Rapid, sustained improvements were seen in 
mood level and stability, cognition and sleep 
in 77% of patients. Only mild side effects were 
seen in some patients. Remission was achieved 
in some patients after stopping treatment.
Paslakis et 
al (2010)
Case series 4 4 patients with de-
pression
Therapeutic outcomes, patient 
tolerance, and side effects to daily 
1.25 mg/kg of oral S-ketamine for a 
maximum of 14 days.
Two patients with melancholic depression saw 
rapid and sustained improvements in mood. 
Two patients with somatic symptoms and other 
comorbid personality disorders showed minimal 
benefit from treatment. No side effects were 
observed.
* Levels of evidence in a research article:
  1a = Systematic reviews (with homogeneity) of randomized controlled trials
  1b = Individual randomized controlled trials (with narrow confidence interval)
  1c = All or none randomized controlled trials
  2a = Systematic reviews (with homogeneity) of cohort studies
  2b = Individual cohort study or low quality randomized controlled trials (e.g. <80% follow-up)
  2c = "Outcomes" Research; ecological studies
  3a = Systematic review (with homogeneity) of case-control studies
  3b = Individual case-control study
  4 = Case-series (and poor quality cohort and case-control studies)
  5 = Expert opinion without explicit critical appraisal, or based on physiology, bench research or "First principles"
Table 1. Studies Evaluating Intranasal/Oral Ketamine in Treatment-Resistant Depression
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Oral Ketamine
Patients with TRD
Three studies in which oral ketamine was administered to pa-
tients with TRD but no other significant comorbidities met the 
inclusion criteria of this review. A retrospective case series was 
conducted among 31 inpatients with TRD, a majority (29 of 31 
patients) of whom received only oral forms of ketamine, and 
22 of 31 received only a single dose of 0.5 mg/kg during the 
duration of the study.23 Goals of this study were to evaluate 
therapeutic improvement, time to therapeutic effect, and any 
adverse effects for three weeks following treatment using the 
Clinical Global Impression Scale.23 They found that 93% of pa-
tients had a positive response in days 0-3 and 80% in days 
4-7 post-ketamine, and that more than 50% of patients had 
improved outcomes during the entire three weeks of study. No 
patients rated their symptoms as worse than before treatment. 
Seven subjects (45%), however, experienced disorientation, 
36% had hallucinations or sedation and 15% had insomnia, 
delusions or anxiety.23
Another study evaluated the effects of 3 mg sublingual doses 
of ketamine every two to three days for no more than six mon-
ths in 26 outpatients with TRD.24 Although this study evaluated 
sublingual ketamine, an exception was made to the inclusion 
criteria outlined in the methods due to the dearth of literature 
on this topic and comparability of the results and study de-
sign. Unlike the previous study,23 effects of the treatment in 
this study were determined based on patients’ self-rated mood 
(using a scale of 0-10) 90 minutes after each treatment. Self-ra-
ted mood, cognition, and sleep increased by at least two points 
in 77% of patients after 90 minutes. Only 12% of patients repor-
ted post-treatment side effects, of which light-headedness was 
most common. These effects lasted less than thirty minutes. 
Remission was achieved in 23% of patients after stopping ke-
tamine treatment. The length of remission varied among pa-
tients, but ranged from seven to 36 days post-treatment. 
A third case series evaluated therapeutic outcomes in four pa-
tients with TRD after administering daily oral doses of 1.25 mg/
kg of ketamine for a maximum of 14 days.25 Using the Hamilton 
Rating Scale for Depression (HRSD), two of the patients had 
self-rated 12 and 13-point reductions in HRSD scores in the first 
week while the other two had a one point reduction and one 
point increase, respectively. Reports of statistical significance 
were not provided because the study was a case series. The 
variation in response was suspected to be due to comorbid 
conditions, including personality disorders. None of the four 
patients in this case series experienced any side effects.
Patients with TRD + Anxiety
Many patients who suffer from depression also have comorbid 
symptoms that can affect the success of treatment, which may 
be a major reason why these patients are resistant to traditio-
nal treatment approaches.25 Both of the studies included in this 
review were conducted using oral ketamine in patients with 
TRD + anxiety.19,26 Both studies used a consistent dosage of 0.5 
mg/kg, and the primary tool used in both studies to measure 
therapeutic outcomes in patients was the Hospital Anxiety De-
pression Scale. 
A case series was conducted on two patients with data co-
llected after one and two hours for both patients, then again 
at day eight (2nd patient only) and day fifteen (1st patient 
only) after treatment.26 Both patients showed an approximately 
50% improvement in both anxiety and depressive symptoms 
(statistical significance was not reported), and neither expe-
rienced side effects or changes in cognitive function, as me-
asured through a Mini-Mental State Exam. Another trial used 
an “open-label” design with 14 patients, in which no randomi-
zation occurs, all 14 patients received treatment, and patients 
were allowed to continue taking other prescribed medications.19 
Patients’ ratings of overall depression and anxiety symptoms 
were collected at baseline and at days 3, 7, 14, 21, and 28. The 
eight subjects who completed the trial all showed more than 
a 30% improvement in anxiety and depressive symptoms, with 
maximums being reached at day three for anxiety and day 14 
for depression. The other six patients withdrew from the study 
due to either a lack of response to ketamine or as a result of 
mental status changes unrelated to the ketamine treatment. 
Thirteen percent of patients in the study reported experiencing 
diarrhea and insomnia.19 
IV vs. Alternative Dosage Forms
This review found that there have been 15 case studies, 11 
open label trials, and nine RCTs studying the effects of keta-
mine in treating MDD. Of the 15 case studies, nine evaluated 
IV administration, four oral administration, two intramuscular 
administration, and one IN administration. Ten of the open la-
bel trials evaluated IV administration and one evaluated oral 
administration. Eight of the RCTs assessed IV administration, 
while one assessed IN administration. The forthcoming discus-
sion will begin by comparing and contrasting the study design, 
response to treatment, and side effect profiles among the IV, 
oral, and intranasal studies. 
Study Design
Single-infusion RCTs. The first study on the use of single-dose 
IV ketamine was an RCT where eight patients were either given 
a 0.5 mg/kg infusion of ketamine over 40 minutes or saline as 
control.27 A common feature shared by all follow-up RCTs on IV 
administration is the administration of 0.5 mg/kg of ketamine 
over 40 minutes. Another common feature to three of the nine 
RCTs is that the patients suffered from both TRD and anxiety di-
sorder.7,28,29 The other three RCTs investigating IV dosage forms 
only evaluated patients with TRD.30,31 A unique feature of one 
of the RCTs was that patients were given a two-week drug-free 
period before initiating treatment, and were evaluated at eight 
time intervals post-infusion.16
The final RCT was the first study of its kind because it evaluated 
the administration of IN ketamine to patients with TRD.18 Pa-
tients in the study group received a total of 50 mg of ketamine 
over 20 minutes. This is an interesting approach, as the lack 
of body weight adjustment could have drastically altered the 
effects on individual patients depending on their body size. 
Another confounding factor that could affect the efficacy of this 
therapy is that 15% of patients in the study had a history of 
medical or recreational drug use.18 
Open label trials. A novel approach used in one open label 
trial involved repeated doses of ketamine for patients who had 
shown an initial response to treatment.32 After the last infusion, 
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patients were monitored twice per week for one month, or 
until a relapse in symptoms occurred. Unlike this trial,32 some 
studies just provided the single dose in the open-label format, 
whereas two others pre-treated patients with lamotrigine (300 
mg) and then did a subsequent randomization of patients who 
responded to the initial ketamine treatment to receive riluzole 
(100-200 mg) or placebo to try and not only minimize the psy-
chomimetic side effects of ketamine but also prolong its phar-
macologic activity in the body.30,33 These side effects of ketami-
ne have been associated with increased pre-synaptic glutamate 
release.8,34 It was hoped that by using additional drugs that act 
on glutamate receptors, the acute neuropsychiatric effects of 
ketamine would be reduced.
The final open label trial followed patients intermittently for 
three weeks after they received a 0.5 mg/kg dose of oral ke-
tamine.19 It is suggested that future studies include more fre-
quent follow-up using standardized, validated clinical tools, 
and measure outcomes over longer periods of time.
Case series. Nine of the 15 case series conducted to date have 
focused on IV administration. Of these, six have used the most 
common dosage formulation of 0.5 mg/kg injected over a time 
frame of 40-60 minutes. However, one study used a smaller 
dose of 0.3 mg/kg that was delivered over five days.35 Two other 
studies involved larger doses of ketamine (1-1.5 mg/kg), which 
were administered intramuscularly (IM).36,37 The other four case 
series to date have studied the two more novel dosage forms 
of ketamine – one IN and the other three using oral forms.22-25 
Response to Treatment
Single-infusion RCTs. The first RCT found that ketamine reduced 
HRSD scores within four hours, and that scores were reduced 
by more than 50% by 72 hours post-infusion.15 Each of the 
other seven RCTs on IV administration conducted to date had a 
greater than 50% reduction in scores within 24 hours according 
to standardized measures of clinical depression. In a follow-up 
RCT, it was found that 35% of patients maintained this response 
and 12% sustained remission of symptoms for two weeks.16
A trial on IN ketamine found that 44% of patients had sufficient 
responses to treatment using MADRS scores within 24 hours 
compared to 6% of placebo.18 Despite the apparent lack of lon-
ger term response in this study, the number needed to treat 
was only 2.6, which was the lowest result of any of the RCTs. 
This indicates that, although blood concentration levels of IN 
ketamine were lower than with IV forms, IN ketamine was no 
less effective and merely dissipated more rapidly. 
Open label trials. The repeated-infusion approach demonstra-
ted an 85% reduction in MADRS scores at the completion of 
the trial.32 On average, relapse occurred 19 days after the sixth 
infusion. The other open label trials evaluating IV administra-
tion found consistent improvements in depressive symptoms 
24 hours after treatment.28,30,38-42 However, it remains a mystery 
why some patients who initially respond to treatment relapse 
by 72 hours while others can remain in remission for more 
than two weeks. Although one group of researchers explained 
the variation between treatment groups to be a result of low 
sample sizes,33 this is unlikely given the relatively small size of 
all studies done to date on the use of ketamine for TRD. Other 
potential explanations for the wide variation in relapse times 
may include, but not be limited to, the impacts of ketamine 
on multiple neural pathways within the brain.12,41 Another po-
tential explanation describes, for example, how patients who 
have a family history of alcohol dependence have shown fewer 
dissociative effects and greater improvements in mood compa-
red to control groups.6 These findings have been supported in 
other research, which have also found that patients associated 
with alcohol dependence have better short-term outcomes and 
faster improvement time compared to patients without a family 
history of alcohol dependence.40,43,44
The only open label trial that has been conducted on oral ad-
ministration of ketamine found a similar response rate (57%) 
to that in other trials involving IV administration.19 One major 
difference between this trial and others using IV administration 
was the prolonged time to therapeutic effect. Oral forms of ke-
tamine took 14 days to maximize improvements in symptoms 
of depression rather than several hours as seen with IV forms. 
Despite this delayed onset time, improvements in symptom 
control were more prolonged after oral administration, as pa-
tients experienced remission for up to four weeks.
Case series. There is a high degree of variation in the dosage 
forms and timing of dosing in the case series that have been 
conducted. This makes it difficult to draw general conclusions 
or to compare and contrast the results of this research. Con-
sistency in side effects was noted among these case studies 
when compared to open label trials using IV administration. 
Transient changes were noted in some patients soon after infu-
sion, but these appeared to be mild and did not persist beyond 
24 hours.45
With little exception, each of the five case series (four oral, one 
IN) conducted on novel dosage forms found that patients had 
substantial post-treatment reductions in symptoms of depres-
sion, anxiety, and other associated symptoms like insomnia. 
Variation in the onset of therapy as well as the time to relapse 
appeared to be most strongly correlated to the volume and 
frequency of the dose. Out of the five studies, the study on su-
blingual ketamine used the most consistent and prolonged do-
sage frequency, providing 0.5 mg/kg every two to three days for 
up to six months.24 This provided an indication of ketamine’s 
potential if used on a longer term basis. Although this study 
evaluated sublingual ketamine, this is still a more feasible 
treatment form compared to IV or IM administrations becau-
se it can provide the advantage of patient self-administration. 
Most studies to date have not continued dosing for this length 
of time, or had follow up beyond two weeks. This is an area of 
research that is lacking, denoting the importance of long-term 
evaluations of ketamine’s impact on patients with TRD.
Side Effects
Despite the inroads that ketamine has demonstrated in relie-
ving symptoms of TRD, studies consistently find that patients 
experience one or more psychomimetic, cognitive, or other de-
trimental side effects as a result of treatment.6,15 Although some 
of these effects may be described as mild and transient, the 
lack of evidence regarding long-term ketamine use raises con-
cern over the neurological effects of more frequent and chronic 
ketamine use. Additionally, even if effects are mild and tem-
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but rather data based solely on patients’ self-reported feelings 
or subjective reports from family members.24 Furthermore, the 
lack of consistency with dosing raises questions about ideal 
dosing quantities and frequencies for different administration 
methods which should be studied over longer time periods. 
Despite the shortcomings of the available evidence, the con-
sistent nature of the results demonstrates the need for larger 
population, stratified studies in double-blind, randomized con-
trolled trials.
Future Directions
Now that more precise IV dosing quantities of ketamine have 
proven to be effective for TRD patients, a goal of future studies 
should be to determine more precise dosing quantities and fre-
quencies for oral and IN administrations. This information can 
then be extended to trials on patients with TRD as well as other 
mental or physical comorbidities. This will provide a more accu-
rate understanding of the reasons for various outcomes in these 
patients and how ketamine dosing can be altered so all patients 
with TRD can benefit from both rapid relief of symptoms and 
longer remission from depression.
More recent research efforts have focused on evaluating keta-
mine’s molecular and pharmacologic activity.47-49 Studies have 
further demonstrated ketamine’s rapid and long-lasting ability 
to increase glutamate levels in the ventral hippocampus and 
PFC via mammalian target of rapamycin (mTOR) signaling.47,48 
Additional evidence has shown that ketamine’s antagonism of 
NMDA receptors can trigger a cascade of molecular activity that 
prevents the degradation of mTOR signals, which in turn po-
tentiates ketamine’s anti-depressant effects.49 Continued eva-
luation of ketamine’s pharmacologic potential may lead to the 
discovery of novel targets for rapid anti-depressant therapies in 
patients with TRD.
Another area of future research could be to find ways to optimi-
ze ketamine metabolism in the brain so its therapeutic effects 
can be prolonged. Two studies tried to optimize the delivery of 
IV ketamine and minimize side effects by pre-treating patients 
who initially responded to ketamine using lamotrigine and ri-
luzole.30,33 However, this was unsuccessful at curbing remission 
compared to placebo, which highlights the need for further in-
vestigation into strategies for preventing relapse post-ketamine 
treatment. A better understanding of the action of ketamine on 
neural circuits in the CNS could allow for the development of 
other therapeutic combinations that enhance ketamine’s bene-
ficial effects.41
The positive findings in this review regarding the effectiveness 
of oral administration may not only make treatment with oral 
ketamine more attractive to patients but also reduce the risk 
of adverse outcomes associated with IV catheters, such as mal-
function, infection, and thrombosis.50,51 Although more research 
is needed in larger, more controlled research conditions, re-
sults from studies thus far can be used as a basis for future 
research.19
The studies on IN administration show that lower doses of ke-
tamine can still have beneficial effects, and with fewer side 
effects than standard IV preparations.18,22 More trials into IN 
dosages may result in a better balance between maximizing 
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porary, an analysis of how this can impact patients who are 
employed or must be functional with daily activities of living 
has yet to be established. 
An open label trial found similar side effects to the single-infu-
sion RCTs described previously.32 Most studies to date that have 
evaluated IV administration have discovered limited side effects 
in a select few patients, which dissipated within one day of 
infusion.6,24 However, this information should be weighed with 
caution given the lack of standardized testing that was used to 
interpret side effects. With one exception,31 most studies to date 
have not used validated data collection tools for evaluating side 
effects. This should be done in future studies so results can be 
more easily compared.
The administration of IN ketamine has demonstrated a relati-
ve lack of cognitive, psychomimetic, or other side effects.18 It 
is promising that the body of research conducted to date has 
demonstrated few severe or lasting side effects associated with 
ketamine treatment, regardless of dosage form.4,5,46 
Limitations of the Included Studies
All of the studies in this review were conducted with very small 
sample sizes. The largest study evaluated 31 patients, which 
lowers the power of the results and means the results may be 
less applicable to the broader population. Four of the seven 
studies in this review had statistically significant results.18,19,22,23 
Another limitation of the studies presented in this review is the 
predominance of case series. This type of study lacks an appro-
priate control, making it a low-quality study design. As a result, 
ketamine is controlled to placebo, rather than with the currently 
accepted standard treatment. This highlights the need for future 
studies to use hypothesis-testing study designs such as cohort 
studies or RCTs with the aim of generating evidence-based re-
sults. Lastly, the varying degree of statistical significance repor-
ted in the seven studies included in this review may bring into 
question the true efficacy of IN and oral ketamine.24-26 
Another issue is the degree of variation within the different 
population subtypes that are included as treatment groups. In-
teractions of ketamine with other drugs, comorbid conditions 
(e.g. anxiety disorder, bipolar depression), and the metabolism 
of individual patients may drastically alter the efficacy and po-
tency of ketamine in patients with TRD. One study found that 
most patients with substance abuse disorders could not tolera-
te the withdrawal period prior to treatment.31 As a result, only 
patients who could withstand withdrawal from their medica-
tion(s) and the psychotropic side effects of ketamine continued 
with the study. These factors should be taken into consideration 
when analyzing and interpreting results from these studies.7,27 
As shown in Table 1, the evidence in this review, while promi-
sing, lacks the quality and quantity that would allow for more 
definitive conclusions. Of the seven studies, only one is an RCT 
- the highest (and most desirable) level of evidence (Level 1),13 
another is an open-label proof-of-concept trial, which is consi-
dered a low quality controlled trial (Level 2b),19 and the other 
five are case series (Level 4), the second-lowest level of eviden-
ce in research (Table 1). Lastly, studies that have evaluated the 
side effects patients experience post-ketamine treatment have 
not used objective, standardized, and validated clinical tools 
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clinical benefits and minimizing side effects.
Conclusion
The studies of IV, oral, and IN administration forms of ketamine 
in treating TRD support the hypothesis of this paper. Oral and 
IN administration forms of ketamine have demonstrated thera-
peutic outcomes in some patients with TRD. Further studies will 
be needed to verify this, but given the relative lack of effective 
therapies for TRD combined with the challenges of long-term 
maintenance of treatment, safety, and ease of administration of 
these novel dosage forms, more research is certainly warranted.
References
1. Marcus M, Yasamy MT, van Ommeren M, Chisholm D, Saxena S. Depression: 
a global public health concern. Geneva: World Health Organization Depart-
ment of Mental Health and Substance Abuse; 2012.
2. American Psychiatric Association. Diagnostic and statistical manual of men-
tal disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
3. Wijeratne C, Sachdev P. Treatment-resistant depression: critique of current 
approaches. Aust N Z J Psychiatry. 2008 Sep;42(9):751-62.
4. Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK. Ketamine as the prototype 
glutamatergic antidepressant: pharmacodynamics actions, and a systema-
tic review and meta-analysis of efficacy. Ther Adv Psychopharmacol. 2014 
Apr;4(2):75-99.
5. Katalinic N, Lai R, Somogyi A, Mitchell PB, Glue P, Loo CK. Ketamine as a new 
treatment for depression: a review of its efficacy and adverse effects. Aust N 
Z J Psychiatry. 2013 Aug;47(8):710-27.
6. Naughton M, Clarke G, O’Leary OF, Cryan JF, Dinan TG. A review of ketamine 
in affective disorders: current evidence of clinical efficacy, limitations of use, 
and pre-clinical evidence on proposed mechanisms of action. J Affect Disord. 
2014 Mar;156:24-35.
7. Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, et al. 
Randomized controlled crossover trial of ketamine in obsessive-compulsive 
disorder: proof-of-concept. Neuropsychopharmacology. 2013 Nov;38(12):2475-
83.
8. Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, et al. Ketami-
ne for treatment-resistant unipolar depression: current evidence. CNS Drugs. 
2012 Mar 1;26(3):189-204.
9. Krishnan V, Nestler EJ. Linking molecules to mood: new insight into the 
biology of depression. Am J Psychiatry. 2010 Nov;167(11):1305-20.
10. Price JL, Drevets WC. Neurocircuitry of mood disorders. Neuropsychophar-
macology. 2010 Jan;35(1):192-216.
11. Opler LA, Opler MG, Arnsten AF. Ameliorating treatment-refractory depres-
sion with intranasal ketamine: potential NMDA receptor actions in the pain 
circuitry representing mental anguish. CNS Spectr. 2016 Feb;21(1):12-22.
12. Abel KM, Allin MP, Kucharska-Pietura K, David A, Andrew C, Williams S, et 
al. Ketamine alters neural processing of facial emotion recognition in healthy 
men: an fMRI study. Neuroreport. 2003 Mar 3;14(3):387-91. 
13. Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, et al. Effects of 
NMDA antagonism on striatal dopamine release in healthy subjects: applica-
tion of a novel PET approach. Synapse. 1998 Jun;29(2):142-7.
14. Salvadore G, Cornwell BR, Sambataro F, Latov D, Colon-Rosario V, Carver F, 
et al. Anterior cingulate desynchronization and functional connectivity with 
the amygdala during a working memory task predict rapid antidepressant 
response to ketamine. Neuropsychopharmacology. 2010 Jun;35(7):1415-22.
15. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et 
al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 
2000 Feb 15;47(4):351-4.
16. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et 
al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-re-
sistant major depression. Arch Gen Psychiatry, 2006 Aug;63(8):856-64.
17. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewsk SR. The STAR*D Pro-
ject results: a comprehensive review of findings. Curr Psychiatry Rep 2007 
Dec;9(6):449-59.
18. Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, et 
al. A randomized controlled trial of intranasal ketamine in major depressive 
disorder. Biol Psychiatry. 2014 Dec;76(12):970-6.
19. Irwin SA, Iglewicz A, Nelesen RA, Lo JY, Carr CH, Romero SD, et al. Daily oral 
ketamine for the treatment of depression and anxiety in patients receiving 
hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med. 2013 
Aug;16(8):958-65.
20. Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Slonena EE, Vande 
Voort JL, et al. Effect of baseline anxious depression on initial and sustained 
antidepressant response to ketamine. J Clin Psychiatry. 2014 Sep;75(9):e932-8. 
21. Curran HV, Morgan C. Cognitive, dissociative and psychogenetic effects 
of ketamine on recreational users on the night of drug use and 3 days later. 
Addiction. 2000 Apr;95(4):575-90.
22. Papolos DF, Teicher MH, Faedda GL, Murphy P, Mattis S. Clinical experience 
using intranasal ketamine in the treatment of pediatric bipolar disorder/fear 
of harm phenotype. J Affect Disord. 2013 May;147(1-3):431-6.
23. Iglewicz A, Morrison K, Nelesen RA, Zhan T, Iglewicz B, Fairman N, et al. 
Ketamine for the treatment of depression in patients receiving hospice care: 
a retrospective chart review of thirty-one cases. Psychosomatics. 2015 Jul-
Aug;56(4):329-37.
24. Lara DR, Bisol LW, Munari LR. Antidepressant, mood stabilizing and pre-
cognitive effects of very low dose sublingual ketamine in refractory unipolar 
and bipolar depression. Int J Neuropsychopharmacol. 2013 Oct;16(9):2111-17.
25. Paslakis G, Gilles M, Meyer-Lindenberg A, Deuschle M. Oral administration 
of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: 
a case series. Pharmacopsychiatry. 2010 Jan;43(1):33-5.
26. Irwin SA, Iglewicz A. Oral ketamine for the rapid treatment of depres-
sion and anxiety in patients receiving hospice care. J Palliat Med. 2010 
Jul;13(7):903-8.
27. Niciu MJ, Luckenbaugh DA, Ionescu DF, Guevara S, Machado-Vieira R, Ri-
chards EM, et al. Clinical predictors of ketamine response in treatment-resis-
tant major depression. J Clin Psychiatry. 2014 May;75(5):e417-23.
28. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Kha-
life S, et al. A randomized add-on trial of an N-methyl-D-aspartate antago-
nist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010 
Aug;67(8):793-802.
29. Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, 
Cravchik A, et al. Replication of ketamine’s antidepressant efficacy in bipolar 
depression: a randomized controlled add-on trial. Biol Psychiatry. 2012 Jun 
1;71(11):939-46.
30. Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney 
DS. Riluzole for relapse prevention following intravenous ketamine in treat-
ment-resistant depression: a pilot randomized, placebo-controlled continua-
tion trial. Int J Neuropsychopharmacol. 2010 Feb;13(1):71–82.
31. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al. 
Antidepressant efficacy of ketamine in treatment-resistant major depression: 
a two-site randomized controlled trial. Am J Psychiatry. 2013 Oct;170(10):1134-
42.
32. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, 
et al. Safety and efficacy of repeated-dose intravenous ketamine for treat-
ment-resistant depression. Biol Psychiatry. 2010 Jan;67(2):139-45.
33. Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Krons-
tein P, et al. Course of improvement in depressive symptoms to a single 
intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, 
double-blind, placebo-controlled study. Neuropsychopharmacology. 2012 
May;37(6):1526-33.
34. Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic 
system to develop novel, improved therapeutics for mood disorders. Nat Rev 
The International Journal of Medical StudentsInt J Med Students   •   2016  |  May-Aug  |  Vol  4  |  Issue 2 71
Review
Drug Discov. 2008 May;7(5):426-37.
35. Correll GE, Futter GE. Two case studies of patients with major depressive 
disorder given low-dose (subanesthetic) ketamine infusions. Pain Med. 2006 
Jan-Feb;7(1):92-5.
36. Glue P, Gulati A, Le Nedelec M, Duffull S. Dose- and exposure-response to 
ketamine in depression. Biol Psychiatry. 2011 Aug 15;70(4):e9-10.
37. Goforth HW, Holsinger T. Rapid relief of severe major depressive disorder 
by use of preoperative ketamine and electroconvulsive therapy. J ECT. 2007 
Mar;23(1):23-5.
38. Machado-Vieira R, Manji HK, Zarate CA. The role of the tripartite glutama-
tergic synapse in the pathophysiology and therapeutics of mood disorders. 
Neuroscientist. 2009 Oct;15(5):525-39.
39. Ibrahim L, Diazgranados N, Luckenbaugh DA, Machado-Vieira R, Baumann 
J, Mallinger AG, et al. Rapid decrease in depressive symptoms with an N-me-
thyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsy-
chopharmacol Biol Psychiatry. 2011 Jun 1;35 (4):1155-9.
40. Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA Jr. 
Family history of alcohol dependence and initial antidepressant response to 
an N-methyl-D-aspartate antagonist. Biol Psychiatry. 2009 Jan 15;65(2):181-4.
41. Salvadore G, Cornwell BR, Colon-Rosario V, Coppola R, Grillon C, Zarate CA 
Jr, et al. Increased anterior cingulate cortical activity in response to fearful 
faces: a neurophysiological biomarker that predicts rapid antidepressant res-
ponse to ketamine. Biol Psychiatry. 2009 Feb 15;65(4):289-95.
42. Salvadore G, van der Veen JW, Zhang Y, Marenco S, Machado-Vieira R, Bau-
mann J, et al. An investigation of amino-acid neurotransmitters as potential 
predictors of clinical improvement to ketamine in depression. Int J Neuropsy-
chopharmacol. 2012 Sep;15(8):1063-72.
43. Krystal JH, Petrakis IL, Krupitsky E, Schutz C, Trevisan L, D’Souza DC. NMDA 
receptor antagonism and the ethanol intoxication signal: form alcoholism risk 
to pharmacotherapy. Ann N Y Acad Sci. 2003 Nov;1003:176-84. 
44. Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. Ketamine for de-
pression: Where do we go from here? Biol Psychiatry. 2012 Oct;72(7):537-47.
45. Petrakis IL, Limoncelli D, Gueorguieva R, Jatlow P, Boutros NN, Trevisan L, et 
al. Altered NMDA glutamate receptor antagonist response in individuals with 
a family vulnerability to alcoholism. Am J Psychiatry. 2004 Oct;161(10):1776-82.
46. Howland RH. Ketamine for the treatment of depression. J Psychosoc Nurs 
Ment Health Serv. 2013 Jan;51(1):11-4.
47. Wohleb ES, Gerhard D, Thomas A, Duman RS. Molecular and cellular me-
chanisms of rapid-acting antidepressants ketamine and scopolamine. Curr 
Neuropharmacol. 2016 Mar 8. [Epub ahead of print]
48. Carreno FR, Donegan JJ, Boley AM, Shah A, DeGuzman M, Frazer A, et al. 
Activation of a ventral hippocampus-medial prefrontal cortex pathway is both 
necessary and sufficient for an antidepressant response to ketamine. Mol 
Psychiatry. 2015 Dec 1. [Epub ahead of print]
49. Harraz MM, Tyagi R, Cortés P, Snyder SH. Antidepressant action of keta-
mine via mTOR is mediated by inhibition of nitrergic Rheb degradation. Mol 
Psychiatry. 2016 Mar;21(3):313-9.
50. Monreal M, Davant E. Thrombotic complications of central venous cathe-
ters in cancer patients. Acta Haematol. 2001;106(1-2):69-72.
51. Kurul S, Saip P, Aydin T. Totally implantable venous-access ports: local 
problems and extravasation injury. Lancet Oncol. 2002 Nov;3(11):684-92.
Twohig PA, et al. Using Oral and Intranasal Dosage Forms of Ketamine for Managing Treatment-Resistant Depression
Acknowledgments
The authors would like to thank Saba University School of Medicine for endorsing the publication of this review article.
Conflict of Interest Statement & Funding
The authors have no funding, financial relationships, or conflicts of interest to disclose.
Author Contributions
Conceptualization, Critical revision of the manuscript, Approval of the final version: PAT, VH. Data collection, Data analysis and interpretation, 
Writing: PAT. Administrative/technical advice: VH.
Cite as: 
Twohig PA, Huckfeldt V. Using oral and intranasal dosage forms of ketamine for managing treatment-resistant depression: a review of the 
literature. Int J Med Students. 2016 May-Aug;4(2):64-71.
